Tracers / [225Ac]Ac-Macropa-N4MU01
[225Ac]Ac-Macropa-N4MU01
Also written as [Ac-225]Ac-Macropa-N4MU01
- Radionuclide
- Ac-225 t½ 14284.8 min
- Modality
- Therapy
- Production route
- —
- Stage
- Reported once
- Syntheses indexed
- 1
What it is
- Compound class
- Radioimmunoconjugate (anti-Nectin-4 monoclonal antibody, N4MU01, conjugated with Macropa chelator)
- Target / mechanism
- Nectin-4, overexpressed in triple-negative breast cancer, targeted by fully human anti-nectin-4 antibody N4MU01 PMID 39978811
- Clinical application
- Radioimmunotherapy of Nectin-4-positive triple-negative breast cancer PMID 39978811
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | — | more than 95% | greater than 99% | Macropa-N4MU01 | 39978811 2025 J Nucl Med Radiolabeling with 225Ac was performed as previously reported (16). — the radiochemical yield of [225Ac]Ac-Macropa-N4MU01 was more than 95% at a specific activity of 10 kBq/μg |
Need this precursor?We can point you to suppliers for [225Ac]Ac-Macropa-N4MU01, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 39978811. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 39978811: 'The conjugation of N4MU01 with SCN-Macropa for the labeling with 225Ac was performed following the standard operating procedure (supplemental methods).'.